Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: ValuEngine, Inc.
Provider: Reuters Investment Profile

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Mesoblast Ltd Issues New Ordinary Shares

Wednesday, 13 Mar 2013 06:23pm EDT 

Mesoblast Ltd announced that it has issued 26,970,979 ordinary shares at an issue price of AUD 6.30 per share. The shares issued as a targeted private placement for the purpose of funding on-going operations, specifically the proposed phase 3 clinical trial using MPCs for treatment of degenerative disease of the lumbar spine, new phase 2 clinical trials to broaden the indications for intravenous delivery of MPCs in the treatment of systemic inflammatory conditions, optimization of manufacturing processes and increased product inventory and additional capacity for staff costs and overheads. 

Company Quote

0.05 +1.25%
18 Dec 2014